I am a physical chemist with expertise in the field of colloidal science, skilled in experiments, theory and simulations to solve pharmaceutical problems – from small molecules to macromolecules like mRNA.

I have been working at AstraZeneca for over 25 years on gastrointestinal absorption, oral vaccines, molecular simulations, nanop文章 systems of poorly soluble drugs and 更多 recently, on lipid nanop文章s and exosomes incorporating nucleic acids.

I received my PhD at Chalmers University of Technology in 1993. In 2007, I became an adjunct Professor at the Department of Chemistry and Molecular Biology, University of Gothenburg, which enhances my interaction with the academic community.


皇冠官网网站

CURRENT ROLE

皇冠官网

2018

皇冠官网

2017

皇冠官网

2016

皇冠官网

皇冠官网

Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation. 皇冠官网手机版

Cao E,  Lindgren A, Martinsson S,  Hu LJ, Lindfors L, Sigfridsson K, Skantze U, Michaelsson E, Trevaskis NL, Porter CJH. Journal of Controlled Release, (2019), 296: 29. Publication link

Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles.皇冠官网手机版

Arteta MY, Kjellman T, Bartesaghi S, Wallin S, Wu X, Kvistc AJ, Dabkowska A, Székely N, Radulescu A, Bergenholtz J, Lindfors L. Proceedings of the National Academy of Sciences (2018), 115: E3351. Publication link.

Nanocrystal formulations of a poorly soluble drug. 1. In vitro characterization of stability, stabilizer adsorption and uptake in liver cells.皇冠官网手机版

Sigfridsson K, Skantze U, Skantze P, Johansson S, Grant I,  Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. International Journal of Pharmaceutics (2017), 518: 29.  Publication link.

Nanocrystal formulations of a poorly soluble drug. 2. Evaluation of nanocrystal liver uptake and distribution after intravenous administration to mice. 皇冠官网手机版

Sigfridsson K, Skantze P, Skantze U, Svensson L,  Löfgren L, Nordell P, Michaelsson E, Smedsrød B, Fuglesteg B, Elvevold K, Lindfors L. International Journal of Pharmaceutics (2017), 524: 248. Publication link.

Development of target-specific liposomes for delivering small molecule drugs after reperfused myocardial infarction. 皇冠官网手机版

Krishna Dasa SS, Suzuki R, Gutknecht M, Brinton LT, Tian Y, Michaelsson E, Lindfors L,  Klibanov AL, French BA, Kelly KA. Journal of Controlled Release (2015), 220: 556.  Publication link.

Secondary Crystal Nucleation: Nuclei Breeding Factory Uncovered.皇冠官网手机版

Anwar J, Khan S, Lindfors L. Angewandte Chemie (2014), 127: 14894. Publication link.

Nucleation and crystal growth in supersaturated solutions of a model drug皇冠官网手机版

Lindfors L, Forssén S, Westergren J, Olsson U. Journal of Colloid and Interface Science (2008), 325: 404. Publication link.

Amorphous drug nanosuspensions.1.Inhibition of Ostwald ripening皇冠官网手机版

Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Langmuir (2007), 22: 906. Publication link.

Amorphous drug nanosuspensions.2. Experimental determination of bulk monomer concentrations皇冠官网手机版

Lindfors L, Forssén S, Skantze P, Skantze U, Zackrisson A, Olsson U. Langmuir (2007), 22: 911. Publication link.

Amorphous drug nanosuspensions.3. Particle dissolution and crystal growth 皇冠官网手机版

Lindfors L, Skantze P, Skantze U, Westergren J, Olsson U. Langmuir (2007), 23: 9866.  Publication link.